成人重症哮喘生物制剂治疗后临床缓解的定义与预测因素
基于国际重症哮喘登记处23个国家数据的纵向队列研究,评估成人重症哮喘患者启动生物制剂前后1年内四个哮喘结局域的缓解情况。结果显示50.2%、33.5%、25.8%和20.3%的患者分别达到两域、三域(+控制)、三域(+肺功能)和四域缓解。生物制剂启动前哮喘病程每增加10年,四域缓解的比值比下降15%(OR 0.85,95%CI 0.73-1.00)。
要点
- 启动生物制剂后1年内约五分之一成人重症哮喘患者达到四域缓解。
- 哮喘病程每增加10年,四域缓解几率降低15%(OR 0.85,95%CI 0.73-1.00)。
- 启动前急性发作更少、口服激素剂量更低、控制更好、肺功能更好的患者更易缓解。
核心结论
- 启动生物制剂后1年内约五分之一成人重症哮喘患者达到四域缓解。
- 启动前损害较轻且哮喘病程较短者更易获得缓解,提示若以缓解为目标不应延迟生物制剂治疗。
研究设计与样本
- 纵向队列研究,数据来自国际重症哮喘登记处23个国家。
- 在生物制剂启动前后各1年评估四个哮喘结局域。
主要发现
- 50.2%达到两域缓解(急性发作+长期口服激素)。
- 33.5%达到三域缓解(+控制),25.8%达到三域缓解(+肺功能)。
- 20.3%达到四域缓解。
- 哮喘病程每增加10年,四域缓解的OR为0.85(95%CI 0.73-1.00)。
- 启动前急性发作更少、长期口服激素日剂量更低、控制更好、肺功能更好者缓解几率更高。
关键数值与推荐
- 预设缓解切点:每年0次急性发作、无长期口服激素、哮喘部分/良好控制、FEV1占预计值≥80%。
- 缓解分别按两域(急性发作+长期口服激素)、三域(+控制或+肺功能)和四域定义。
临床怎么用
- 对重症哮喘患者,若以临床缓解为目标,应尽早启动生物制剂治疗。
- 启动前病程短、损害轻、控制好、肺功能好的患者更可能获得多域缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori-defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV1 ⩾ 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73-1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.
引用
- Perez-de-Llano, Scelo, Tran, et al. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024. PMID: 38701495. doi:10.1164/rccm.202311-2192OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。